Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 9/20 | 0.53 |
| ▸ | ABCC1 | P33527 | 2/20 | 0.46 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.41 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | CSF1R | P07333 | 1/20 | 0.40 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12796685 | 0.91 | ABCB1 (0.56) | ABCB1ABCC1NTRK1CYP3A4CYP2C19 | |
| SCHEMBL12796686 | 0.90 | ABCB1 (0.46) | ABCB1ABCC1NTRK1CYP3A4ADORA2B | |
| SCHEMBL12796689 | 0.89 | ABCB1 (0.43) | ABCB1ABCC1NTRK1CYP11B1CYP11B2 | |
| SCHEMBL12796659 | 0.88 | ABCB1 (0.46) | ABCB1ABCC1NTRK1CYP3A4ADORA2B | |
| SCHEMBL12796690 | 0.83 | TYK2 (0.41) | ABCB1CYP3A4ADORA2BCYP2C19CYP11B1 | |
| SCHEMBL12848891 | 0.82 | DYRK1A (0.44) | ABCB1ABCC1CYP3A4ADORA2BCYP2C19 | |
| SCHEMBL12848831 | 0.81 | DYRK1A (0.46) | ABCB1NTRK1CYP3A4ADORA2BCYP2C19 | |
| SCHEMBL12848881 | 0.80 | ABCB1 (0.48) | ABCB1ABCC1CYP3A4CYP2C19ROCK2 | |
| SCHEMBL12848829 | 0.79 | LMNA (0.49) | ABCB1NTRK1CYP11B1CYP11B2CREBBP | |
| SCHEMBL12848873 | 0.79 | ABCB1 (0.46) | ABCB1ABCC1CYP3A4ADORA2BCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110052643-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2011-03-03 | — | — | US | disclosed |
| US-20110052643-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2011-03-03 | — | — | US | disclosed |
| WO-2009089305-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2009-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110052643-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | TSLP, NFATC1, IL5 | ABCB1 435/4885ABCC1 511/4885NTRK1 4313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.